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Case Report
Use of miltefosine in the treatment of visceral leishmaniasis
in children at a tertiary care hospital of Karachi
Khadija Nuzhat Humayun,1 Taimur Saleem,2 Umair Khalid,3 Fyezah Jehan,4 Sajid Soofi5
Department of Pediatrics and Child Health,1,4,5 Medical College,2,3 Aga Khan University, Karachi, Pakistan.
Abstract
Existing standard treatment options for visceral
leishmaniasis are less than optimal. We report here the use of
oral miltefosine in the treatment of two paediatric cases of
visceral leishmaniasis at a tertiary care hospital in Karachi,
Pakistan. One patient came from Balochistan while the
second patient was from Northern Pakistan. Both presented
with a prolonged history of fever, massive
hepatosplenomegaly, anaemia and thrombocytopenia.
Visceral leishmaniasis was diagnosed with bone marrow
studies. Amphotericin B was first started in the first patient;
however severe hypokalaemia and allergic reaction occurred.
Oral miltefosine was then administered. The child showed
clinical improvement with regards to signs of leishmania
infection but succumbed to a nosocomial infection during the
hospital stay. In the second patient, miltefosine was started in
the first instance. He showed remarkable clinical
improvement. At 2 months follow-up, the child showed
adequate weight gain along with successful resolution of
hepatosplenomegaly and fever. Miltefosine has the potential
to be considered a first line therapy for visceral leishmaniasis
in developing countries; however larger studies are warranted
to validate the trends observed in this small case series. 
Introduction
Visceral leishmaniasis (VL) or 'Kalazar' is a serious
parasitic infection of the reticuloendothelial system. Unless
promptly managed, the disease can result in significant
morbidity and mortality especially in the endemic areas.1
Drug resistance has become a major impediment in the
effective treatment of VL. Miltefosine has produced
remarkable results in the last few years and is now rapidly
emerging as an efficacious and cost effective agent in the
treatment of VL. However, there are no reports of the
successful use of miltefosine for the treatment of VL in
Pakistan. Here, we report the first instance of the treatment of
two cases of VL with oral miltefosine in Pakistan.
Case One:
An 8 years old boy from Balochistan province of
Pakistan presented with 11 months history of intermittent
high grade fever, night sweats, severe anorexia, vomiting and
weight loss. He had been empirically treated for malaria and
enteric fever multiple times with no response to any of these
therapies. On examination, he was severely malnourished,
cachectic and extremely pale. His abdomen was distended
with massive hepatosplenomegaly (Figure-1). Laboratory
investigations showed anaemia (haemoglobin=6 g/dl) and
thrombocytopenia (platelets=60,000/L). Bone marrow smear
showed Leishmania Donovani bodies (Figure-2) and a
diagnosis of VL was made. The patient was initially treated
with amphoterecin B. However, the incidence of adverse
effects such as severe hypokalaemia, thrombocytopenia and
allergic reactions dictated the discontinuation of this drug.
Miltefosine was specially arranged for this patient through a
request to the manufacturer as it was not available locally at
that time. He was started on a dose of 2.5mg/kg/day and
showed successful response to therapy. 
His body temperature was the first parameter to
normalize followed by improvement in appetite and weight
gain within 1 week of treatment. The child continued to show
clinical improvement with respect to signs and symptoms of
VL but unfortunately contracted a nosocomial infection
during the hospital stay and succumbed to it. 
Case Two:
A one year 8 months old boy from northern Pakistan
presented with a 6 month history of high grade intermittent
fever, progressive abdominal distension, anorexia and weight
loss. During his treatment at two other cities of Pakistan, he had
received multiple courses of antibiotics and antituberculous
therapy without success. On examination, his height and
weight were below the 5th percentile for age. Abdominal
examination revealed massive hepatosplenomegaly. His
laboratory investigations showed anaemia (haemoglobin=
6.9g/dl), thrombocytopenia (platelets=80,000/L) and a raised
erythrocyte sedimentation rate of 60 mm/hr. A bone marrow
trephine was done which helped clinch the diagnosis of VL by
demonstration of Leishmania Donovani bodies. This patient
was treated in the first instance with oral miltefosine at a dose
of 2.5mg/kg/day. He was discharged on 5th day of therapy to
complete a total of 28 days of treatment on an outpatient basis.
Subsequent follow-ups at 2 weeks and 2 months showed
adequate weight gain along with successful resolution of
hepatosplenomegaly and fever. 
Discussion
Protozoal organisms of Leishmania Donovani
complex, the causative agent of VL, are acquired through
sandfly bites. Untreated cases have a high mortality and
morbidity. An estimated 500,000 cases of VL occur annually
with 90% of the cases occurring in five countries including
India, Bangladesh, Nepal, Sudan and Brazil. The paediatric
population is especially affected by this disease.1 In Pakistan,
the disease is endemic in Northern Pakistan and Azad Jammu
and Kashmir.2 Important confounding diseases include
tuberculosis, enteric fever and malaria because of their high
prevalence in areas where VL is endemic. 
For years, the standard treatment for VL consisted of
daily injections of pentavalent antimony compounds for 28
days. However, this therapy is fraught with many pitfalls such
as reduced efficacy due to drug resistance, difficulties of
administration and increasing frequency and severity of
adverse events such as acute pancreatitis, myalgias,
arthralgias and arrhythmias. Alternatives such as
amphotericin B and pentamidine also have their fair share of
shortcomings. Pentamidine has been virtually abandoned
because of an unfavorable constellation of serious toxicity,
inconvenient scheduling of administration, and no efficacy
advantage. This had led physicians to rely predominantly on
amphotericin B and liposomal amphotericin B for the
treatment of VL. However, increased frequency of adverse
reactions such as electrolyte derangements and anaphylaxis,
necessity of hospital stay for IV injections, problems with
availability and greater cost preclude its use in endemic areas;
many of which form part of the developing world.1,3,4
Developed initially as an anti-neoplastic agent,
miltefosine is currently the only oral treatment available for
VL. Multiple trials have shown that oral miltefosine is an
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Figure-1: Abdomen of first child showing massive hepatosplenomegaly. Also
evident are the cachectic upper extremities.
Figure-2: Smear of bone marrow aspirate showing Leishmania Donovani bodies.
overall highly effective treatment for VL both in adults and in
children. In Pakistan, miltefosine is a newly registered
pharmaceutical compound. To date, only one non-
randomized comparative clinical trial has been conducted in
Pakistan to compare the efficacy of miltefosine and
pentavalent antimony compounds in patients with cutaneous
Leishmaniasis.4
For developing countries, miltefosine may prove to be
more advantageous in the treatment of VL. In the face of
increasing costs incurred from health care and associated
paraphernalia, affordability is a major constraint in the
treatment of many ailments. Standard agents used in the
treatment of VL may not be costly on their own but due
consideration needs to be given to associated expenses
incurred. Although the total cost of amphotericin B for a 20-
day treatment regimen in a 15 kg child is around US $50 (1
US $ = 83.3 Pakistani rupees), other added costs that must be
considered include hospital stay for administration of the
medication, possible need for pre-medication with
antihistamines and steroids, frequent laboratory testing to
check renal function, platelets and electrolytes,
administration of fluids and high risk of nosocomial
infections. Hence, the total expenditure is multiplied
manifold. In contrast, a 28-day cost of miltefosine is currently
around US $145; however this can be administered on an
outpatient basis without the above mentioned adjunct
expenses. This is an extremely important consideration for
the paediatric patient population in many developing
countries where health care expenditure on children may not,
unfortunately, be a priority. In addition, the child is not
unnecessarily exposed to the risk of nosocomial infections.
From this perspective, miltefosine may provide a cost
effective alternative to currently standard agents. 
Although few studies exist on this compound,
miltefosine is generally well-tolerated with minimal and
largely reversible side effects such as gastrointestinal
intolerance. Vomiting and diarrhoea generally lasts only one
to two days. A few patients have also had reversible
nephrotoxicity and hepatotoxicity with this drug but this is
mild-to-moderate. Miltefosine may also increase the risk of
other infections and should be used with caution in
immunosuppressed individuals. Because of its potential to
cause teratogenicity and abortion, miltefosine should not be
given to women of child-bearing age unless pregnancy has
been excluded and rigorous contraceptive precautions are
taken during treatment and for 8 weeks after the completion
of treatment.1,5-8
We turned to miltefosine in the first case because of
the adverse effects experienced with amphotericine B while
our second patient was treated with oral miltefosine in the
first instance. One of our patients succumbed to a nosocomial
infection in the latter part of his hospital stay. Although
acquisition of this severe infection may well be attributable to
the generalized ill health of the child resulting from the
prolonged illness for 11 months; we can't entirely rule out this
event as an adverse effect of miltefosine.
However, we were able to ascertain a gradual
response to miltefosine in the treatment of VL in him as
judged by improvement in signs and symptoms of
leishmaniasis. We didn't encounter any adverse effects of
miltefosine during the treatment of VL in the second patient. 
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